VAXCYTE, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.25 USD | -1.97% |
|
-2.79% | +2.74% |
| Feb. 07 | Vaxcyte Insider Sold Shares Worth $450,369, According to a Recent SEC Filing | MT |
| Feb. 05 | Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage | MT |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
Biological Products | |||||||
Total Assets | 65.7M | 393M | 324M | 1.01B | 1.41B | ||
Interest Expense | -40K | -7K | -7K | -2K | - | ||
CAPEX | -1.2M | -1.16M | -6.56M | -5.85M | -67.88M | ||
EBT | -50.27M | -89.22M | -100M | -223M | -402M | ||
D&A | 1.23M | 1.4M | 3.46M | 9.2M | 10.17M | ||
Operating Income | -54.15M | -89.58M | -104M | -232M | -468M | ||
Net Income | -50.27M | -89.22M | -100M | -223M | -402M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
Total Assets | 65.7M | 393M | 324M | 1.01B | 1.41B | ||
Interest Expense | - | -7K | -7K | -2K | - | ||
D&A | - | 1.4M | 3.46M | 9.2M | 10.17M | ||
CAPEX | - | -1.16M | -6.56M | -5.85M | -67.88M | ||
Net Income | - | -89.22M | -100M | -223M | -402M | ||
EBT | - | -89.22M | -100M | -223M | -402M | ||
Operating Income | - | -89.58M | -104M | -232M | -468M |
- Stock Market
- Equities
- PCVX Stock
- Financials Vaxcyte, Inc.
- Business Segments